抄録
The effects of angiotensin II type 1 receptor antagonists on serum uric acid (UA) levels were retrospectively examined between December, 1998 and December, 2001 in patients who received 50 mg losartan potassium (LOS) or 8 mg candesartan cilexetil (CAN) per day for 12 months without any change in the prescription over 12 months after initiation of administration. Serum creatinine level at baseline was below 1.2 mg/dL.
Patients having a pretreatment level of serum UA within the normal range (UA≤7.0 mg/dL) and receiving LOS were arbitrarily assigned as NLOS (n=34) and those exceeding the normal range, as HLOS (n24). Similarly, NCAN (n=35) and HCAN (n=30) were assigned, respectively.
In all NLOS, HLOS, NCAN and HCAN groups, no change was observed in urea nitrogen or serum creatinine level at 12 months after administration of the drugs. The serum UA level was decreased significantly after administration in HLOS group, whereas no significant change was noted in NLOS group-Although the serum UA level was increased significantly at 12 months as compared with the pretreatment value in NCAN group, the levels remained within the normal range. The serum UA levels stayed within the normal range in HCAN group.
Among those who were treated with LOS at a dose of 50 mg per day, serum uric acid levels 12 months after administration showed no change as compared with the pretreatment values in patients with normal renal function and UA≤7.0 mg/dL. Further, the serum uric acid levels after 12 months significantly decreased to 7.0 mg/dL or below as compared with the pretreatment values in patients with UA>7.0 mg/dL. These results might be attributed to the lowering effect of LOS.
This retrospective study suggested that LOS has a lowering effect on serum uric acid levels in patients with hyperuricacidemia but CAN has no such effect.
